IGM Biosciences to Present at Four Upcoming Investor Conferences - Sep 02, 2020
MOUNTAIN VIEW, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at four upcoming investor conferences:
- Baird 2020 Global Healthcare Conference on Wednesday, September 9 at 3:10 p.m. ET.
- H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16 at 1:00 p.m. ET.
- 2020 Cantor Global Virtual Healthcare Conference on Thursday, September 17 at 4:40 p.m. ET.
- Morgan Stanley 18th Annual Global Healthcare Conference on Friday, September 18 at 11:45 a.m. ET.
A live webcast of the events will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcasts will be archived on the Company’s website for 90 days following the event.
About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.